Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Forecasted Market Size Estimates For The Chemotherapy-Induced Anemia Market Between 2025 And 2029?
The chemotherapy-induced anemia market size has shown significant growth in recent years. It is forecast to increase from $2.62 billion in 2024 to $2.81 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.3%. This historical growth can be attributed to several factors including the rising prevalence of cancer and chemotherapy treatments, an aging population leading to higher cancer incidence, the expansion of chemotherapy drugs and regimens, improvements in overall cancer survival rates, and enhanced awareness and diagnosis of anemia as a side effect.
The chemotherapy-induced anemia market size is projected to undergo significant expansion in the next few years. This market is set to expand to $3.8 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.9%. The growth anticipated during the forecast period stems from factors such as the advancement of supportive care in oncology, an increase in healthcare expenditure and infrastructure, the development of personalized medicine and targeted cancer therapies, the incorporation of biomarker-driven treatment strategies, a growing emphasis on early detection and intervention, and the integration of digital health technologies in patient management. Prominent trends expected in the forecast period include the innovation of novel chemotherapy agents, the integration of machine learning, continuous advancements in cancer research and treatment protocols, the adoption of artificial intelligence, and enhanced collaboration between pharmaceutical companies and healthcare providers.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12513&type=smp
What Are The Key Drivers Of Growth In The Chemotherapy-Induced Anemia Market?
The widespread occurrence of cancer and anemia is projected to fuel the expansion of the chemotherapy-induced anemia market in the foreseeable future. Cancer is defined as a condition where an individual’s cells multiply uncontrollably and spread to other bodily areas. Both cancer and chemotherapy-induced anemia (CIA) are frequently observed in cancer patients who are undergoing aggressive chemotherapy, irrespective of whether radiation therapy is also administered. Medications designed to treat chemotherapy-induced anemia work by stimulating the bone marrow to produce red blood cells. For instance, in 2023, data from Cancer Research UK, an independent UK-based cancer research organization, projected a 3% increase in the incidence of head and neck cancer in the UK between 2023 and 2025, while deaths attributed to these cancers are expected to rise by 12% during the same 2023 to 2025 period. Thus, the high prevalence of cancer and anemia is a primary driver for the growth of the chemotherapy-induced anemia market.
What Are The Major Segment Types Covered In The Chemotherapy-Induced Anemia Market?
The chemotherapy-induced anemiamarket covered in this report is segmented –
1) By Anemia: Mild Anemia; Moderate Anemia; Severe Anemia; Life-Threatening Anemia
2) By Treatment Type: RBC (Red Blood Cells) Transfusion; Erythropoiesis-Stimulating Agents (ESAs); Iron Supplementation
3) By End-User: Hospitals; Ambulatory Surgical Centers; Multispecialty Clinics; Cancer Research Centers; Cancer Rehabilitation Centers
Subsegments:
1) By Mild Anemia: Hemoglobin Levels 10-12 g/dL; Symptomatic Treatments
2) By Moderate Anemia: Hemoglobin Levels 8-10 g/dL; Erythropoiesis-stimulating Agents (ESAs); Blood Transfusion Management
3) By Severe Anemia: Hemoglobin Levels 6.5-8 g/dL; Intensive ESA Treatments; Frequent Blood Transfusions
4) By Life-Threatening Anemia: Hemoglobin Levels Below 6.5 g/dL; Emergency interventions; Critical Care And Monitoring
What Long-Term Trends Will Shape The Future Growth Of The Chemotherapy-Induced Anemia Industry?
Leading companies within the chemotherapy-induced anemia market are concentrating on creating advanced offerings like biosimilars to improve treatment effectiveness and reduce expenditures. Biosimilars are biological medical substances that closely resemble already sanctioned reference biologic medications, showing no significant variations in terms of safety, purity, or overall efficacy. Their purpose is to present more economical alternatives to expensive biologic therapies while ensuring comparable therapeutic results. For instance, in November 2022, Amneal Pharmaceuticals, Inc., a pharmaceutical firm based in the US, introduced RELEUKO (filgrastim-ayow). This particular product draws its reference from Neupogen® and is primarily prescribed for addressing neutropenia, a condition frequently observed in individuals undergoing chemotherapy. It delivers substantial advantages for patients receiving cancer treatment. Its main use is to decrease the occurrence of infections linked to febrile neutropenia in patients receiving myelosuppressive chemotherapy, thereby enhancing their safety and recuperation. Furthermore, RELEUKO® assists in shortening the period for neutrophil recovery and the length of fever following chemotherapy for acute myeloid leukemia, and it helps alleviate the complexities of neutropenia in patients undergoing bone marrow transplantation.
Which Key Market Players Are Investing In Expansion And Innovation Of Chemotherapy-Induced Anemia Market?
Major companies operating in the chemotherapy-induced anemia market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Fresenius Kabi AG, Hospira Inc., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., 3SBio Group, FibroGen Inc., Karger AG, Avesthagen Ltd., Blausen Medical Communications Inc., Aileron Therapeutics Inc.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report
Which Region Shows The Highest Potential For Future Expansion In The Chemotherapy-Induced Anemia Market?
North America was the largest region in the chemotherapy-induced anemia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced anemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request A Customized Version Of The Chemotherapy-Induced Anemia Market Report:
https://www.thebusinessresearchcompany.com/customise?id=12513&type=smp
Browse Through More Reports Similar to the Global Chemotherapy-Induced Anemia Market 2025, By The Business Research Company
Immuno Oncology Drug Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report
Interventional Oncology Devices Global Market Report 2025
Oncology Biosimilar Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model